![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Neuren Rts 07Jul | ASX:NEUR | Australian Stock Exchange | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.00 | - |
Presenting as the featured speaker at the conference, Dr. Joakim Tedroff, Head of Clinical Science at NeuroSearch on Wednesday 10 February, 4pm to 5pm PDT (Thursday, 1am to 2am CET) presented the study results, including the following:
* Efficacy - Results from the MermaiHD study demonstrate that six months' (26 weeks) treatment with Huntexil(R) (45 mg BID), in Huntington's patients significantly improves both voluntary movement control, as measured on the primary endpoint, the mMS, and also a broader range of voluntary and involuntary motor symptoms, including dystonia and eye movements. Measured in both the ITT (Intention to treat) and the PP (per protocol, 82% of patients) populations, the improvements seen were highly statistically significant, and thereby the results in the PP population fully confirm the ITT analysis :
Motor scale; Significance level for the PP population; Significance level
for the ITT population;
Modified Motor Score, mMS; p
1 Year Neuren Rts 07Jul Chart |
1 Month Neuren Rts 07Jul Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions